Loading institutional data...
Loading institutional data...
Held by 720 of 5,944 reporting institutions (98th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $362.31 today, the market must believe free cash flow compounds 24.0%/yr for a decade (off $387M normalized FCF).
The market's 24.0% is more conservative than its 9-yr track record.
2-stage DCF · 0.07B shares · net debt -$589M
mean 37.5% · volatility σ 57% · implied rate exceeded in 5/9 yrs
Central path = implied 24.0%/yr growth; shaded band = ±1σ (57%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 13% of free cash flow, leaving room to grow it and fund buybacks. Last year: $61M dividends + $134M buybacks = $195M returned on $469M FCF.
9 consecutive years of dividend increases · 6%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 15%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $791M covers all $207M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2023-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~0.2% on $203M of debt.
Cash of $791M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-18
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.07B 100.0% | $2.89B 100.0% | $2.95B 100.0% | $2.89B 100.0% | $2.83B 100.0% | $2.15B 100.0% | $1.84B 100.0% | $1.72B 100.0% | $1.60B 100.0% | $1.51B 100.0% |
| Cost of Revenue | $1.97B 64.1% | $1.89B 65.5% | $1.82B 61.7% | $1.75B 60.6% | $1.66B 58.5% | $1.38B 64.2% | $1.23B 67.1% | $1.17B 68.2% | $1.09B 67.9% | $1.01B 66.8% |
| Gross Profit | $1.10B 35.9% | $998.5M 34.5% | $1.13B 38.3% | $1.14B 39.4% | $1.18B 41.5% | $767.8M 35.8% | $605.7M 32.9% | $545.4M 31.8% | $512.9M 32.1% | $501.4M 33.2% |
| Research & Development | $74.3M 2.4% | $69.1M 2.4% | $68.4M 2.3% | $58.5M 2.0% | $52.8M 1.9% | $46.9M 2.2% | $38.9M 2.1% | $40.3M 2.3% | $39.1M 2.4% | $36.8M 2.4% |
| Selling, General & Admin | $393.6M 12.8% | $338.5M 11.7% | $353.4M 12.0% | $316.9M 11.0% | $362.8M 12.8% | $302.0M 14.1% | $272.7M 14.8% | $262.9M 15.3% | $246.0M 15.4% | $239.6M 15.9% |
| Operating Income | $584.9M 19.0% | $569.9M 19.7% | $676.0M 22.9% | $734.0M 25.4% | $752.3M 26.6% | $406.9M 19.0% | $296.6M 16.1% | $240.3M 14.0% | $225.8M 14.1% | $195.2M 12.9% |
| Interest Expense | $500K 0.0% | $3.0M 0.1% | $9.0M 0.3% | $7.9M 0.3% | $8.2M 0.3% | $8.2M 0.4% | $8.5M 0.5% | $8.4M 0.5% | $7.8M 0.5% | $8.1M 0.5% |
| Other Income (Expense), net | -$1.0M -0.0% | -$1.0M -0.0% | $22.0M 0.7% | -$54.1M -1.9% | -$3.4M -0.1% | -$5.6M -0.3% | -$4.8M -0.3% | $400K 0.0% | $3.1M 0.2% | $1.6M 0.1% |
| Pretax Income | $600.9M 19.5% | $585.5M 20.2% | $698.0M 23.7% | $679.9M 23.6% | $748.9M 26.4% | $401.3M 18.7% | $291.8M 15.9% | $240.7M 14.0% | $222.4M 13.9% | $189.8M 12.6% |
| Income Tax Expense | $121.6M 4.0% | $107.5M 3.7% | $122.3M 4.1% | $114.7M 4.0% | $107.2M 3.8% | $72.5M 3.4% | $59.0M 3.2% | $41.4M 2.4% | $80.9M 5.1% | $54.4M 3.6% |
| Net Income | $493.7M 16.1% | $492.7M 17.0% | $593.4M 20.1% | $585.9M 20.3% | $661.8M 23.4% | $346.2M 16.1% | $241.7M 13.1% | $206.9M 12.0% | $150.7M 9.4% | $143.6M 9.5% |
| Per Share | ||||||||||
| EPS (Basic) | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 | $4.68 | $3.27 | $2.80 | $2.04 | $1.96 |
| EPS (Diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 |
| Weighted Avg Shares (Basic) | 72.3M | 73.0M | 74.3M | 74.4M | 74.4M | 73.9M | 74.0M | 73.9M | 73.9M | 73.3M |
| Weighted Avg Shares (Diluted) | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M | 75.8M | 75.4M | 75.4M | 75.8M | 75.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $829.3B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.0B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $466.9B | 111.8× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $367.5B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $341.5B | 28.5× | 19.8× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $245.6B | 36.7× | 31.7× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $207.8B | 27.1× | 17.8× | 5.7× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $186.3B | 22.1× | 20.3× | 6.3× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.6B | 27.6× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.2B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $149.7B | 41.9× | 30.9× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $139.7B | 50.0× | 38.4× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $129.1B | 33.2× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $128.3B | 18.2× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $117.9B | 24.7× | 12.5× | 3.2× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $112.9B | 63.9× | 11.3× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $105.2B | 32.8× | 18.1× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.0B | 22.8× | 16.1× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.1B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $90.7B | 16.3× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.1B | 18.9× | 19.6× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.5B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| WST | $26.1B | 53.4× | 33.7× | 8.5× | 6.3% | 35.9% | 16.1% | 15.5% | 14.6% | 0.3× | 720 |
Peers = companies sharing WST's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-18
No material risks flagged.
Where each multiple sits in its own 14-yr range · 80th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 68.2 | 67.1 | 64.2 | 58.5 | 60.6 | 61.7 | 65.5 | 64.1 |
| Gross Profit | 31.8 | 32.9 | 35.8 | 41.5 | 39.4 | 38.3 | 34.5 | 35.9 |
| R&D | 2.3 | 2.1 | 2.2 | 1.9 | 2.0 | 2.3 | 2.4 | 2.4 |
| SG&A | 15.3 | 14.8 | 14.1 | 12.8 | 11.0 | 12.0 | 11.7 | 12.8 |
| Operating Income | 14.0 | 16.1 | 19.0 | 26.6 | 25.4 | 22.9 | 19.7 | 19.0 |
| Income Tax | 2.4 | 3.2 | 3.4 | 3.8 | 4.0 | 4.1 | 3.7 | 4.0 |
| Net Income | 12.0 | 13.1 | 16.1 | 23.4 | 20.3 | 20.1 | 17.0 | 16.1 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on WST: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.